Literature DB >> 8306423

Effects of bilirubin infusion on local cerebral glucose utilization in the immature rat.

C Roger1, V Koziel, P Vert, A Nehlig.   

Abstract

The clinical features of kernicterus have been extensively described. However, there are still no data available on a possible correlation between the areas which appear to preferentially accumulate bilirubin and regional changes in cerebral functional activity. Therefore, we applied the quantitative autoradiographic [14C]2-deoxyglucose method to the measurement of local cerebral metabolic rates for glucose (LCMRglc) in immature rats receiving a bilirubin infusion. A loading dose of 160 mg/kg bilirubin in a buffered serum albumin solution was first given to the rats over 15 min. Thereafter, bilirubin was infused at a reduced rate, 64 mg/kg/h. Bilirubin infusion lasted from 2 to 3 h according to the age of the animal, in order to obtain a plasma concentration of bilirubin ranging from 200 to 300 mumol/l over the experimental period. Bilirubin entered the brain without any sign of blood-brain barrier alteration. The [14C]2-deoxyglucose was injected to the animals 45 min before the end of bilirubin infusion. Rats were studied at 3 postnatal ages, 10 (P10), 14 (P14) and 21 days (P21). Hyperbilirubinemia induced widespread decreases in LCMRglc's in all brain areas and at all ages. These decreases were mostly prominent in sensory areas, auditory and visual, as well as in hypothalamic and thalamic regions. Especially at P10, the distribution of LCMRglc's was strikingly heterogeneous in both cerebral cortex and caudate nucleus, appearing as alternate dark and white columns or as alternate dark and light dots, respectively. The data of the present study are in agreement with clinical observations reporting that bilirubin mostly accumulates in the striatum and cranial nerves and that the neurological sequelae of kernicterus are very often hearing loss as well as motor problems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306423     DOI: 10.1016/0165-3806(93)90129-x

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  6 in total

Review 1.  The blood-brain barrier and bilirubin encephalopathy.

Authors:  R P Wennberg
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

2.  Vascular network expansion, integrity of blood-brain interfaces, and cerebrospinal fluid cytokine concentration during postnatal development in the normal and jaundiced rat.

Authors:  Sandrine Blondel; Nathalie Strazielle; Amel Amara; Rainui Guy; Christine Bain; Alix Rose; Laurent Guibaud; Claudio Tiribelli; Silvia Gazzin; Jean-François Ghersi-Egea
Journal:  Fluids Barriers CNS       Date:  2022-06-07

3.  Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy.

Authors:  Silvia Gazzin; Nathalie Strazielle; Claudio Tiribelli; Jean-François Ghersi-Egea
Journal:  Front Pharmacol       Date:  2012-05-18       Impact factor: 5.810

4.  Ex vivo (1)H nuclear magnetic resonance spectroscopy reveals systematic alterations in cerebral metabolites as the key pathogenetic mechanism of bilirubin encephalopathy.

Authors:  Wenyi Hu; Xiaojie Cheng; Xinjian Ye; Liangcai Zhao; Yanan Huang; Huanle Zhu; Zhihan Yan; Xuebao Wang; Xiaojie Wang; Guanghui Bai; Hongchang Gao
Journal:  Mol Brain       Date:  2014-11-26       Impact factor: 4.041

5.  Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice.

Authors:  G Bortolussi; E Codarin; G Antoniali; C Vascotto; S Vodret; S Arena; L Cesaratto; A Scaloni; G Tell; A F Muro
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

6.  A transcriptome analysis identifies molecular effectors of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells.

Authors:  Raffaella Calligaris; Cristina Bellarosa; Rossana Foti; Paola Roncaglia; Pablo Giraudi; Helena Krmac; Claudio Tiribelli; Stefano Gustincich
Journal:  BMC Genomics       Date:  2009-11-19       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.